Please assess the completion status of the following clinical trial:

Trial Title: Clinical Outcomes Following Treatment With SYSTANE® BALANCE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to attend all study visits;~* Must sign an informed consent form;~* Best-corrected visual acuity (BCVA) of 55 letters or better in each eye as assessed using an early treatment diabetic retinopathy study (ETDRS) chart;~* Willing to take study products as directed for entire study;~* Other protocol-specified inclusion criteria may apply.~Exclusion Criteria:~* Women of childbearing potential who are pregnant, plan to become pregnant during the study, breast feeding, or not using adequate birth control methods;~* Contact lens use within 30 days prior to Screening Visit, or unwilling to avoid contact lens use during the course of the study;~* Use of medication excluded by the protocol;~* Diseases, illnesses, infections, or ocular abnormalities excluded by the protocol;~* Ocular surgeries or procedures excluded by the protocol;~* Other protocol-specified exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SYSTANE BALANCE (Type: EXPERIMENTAL): Propylene glycol, 0.6% eye drops, 1 drop in each eye 4 times per day for 35 days
- REFRESH OPTIVE (Type: ACTIVE_COMPARATOR): Lubricant eye drops, 1 drop in each eye 4 times per day for 35 days

Based on this trial design, predict the completion outcome and termination type (if applicable).